大麻和大麻素在治疗多发性硬化症症状中的应用：系统评价综述。
The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.
机构信息
National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney, NSW, 2052, Australia.
Centre for Youth Substance Abuse Research, The University of Queensland, Royal Brisbane and Women's Hospital Brisbane, Brisbane, QLD, 4006, Australia.
出版信息
Curr Neurol Neurosci Rep. 2018 Feb 13;18(2):8. doi: 10.1007/s11910-018-0814-x.
PURPOSE OF REVIEW
Pharmaceutical cannabinoids such as nabiximols, nabilone and dronabinol, and plant-based cannabinoids have been investigated for their therapeutic potential in treating multiple sclerosis (MS) symptoms. This review of reviews aimed to synthesise findings from high quality systematic reviews that examined the safety and effectiveness of cannabinoids in multiple sclerosis. We examined the outcomes of disability and disability progression, pain, spasticity, bladder function, tremor/ataxia, quality of life and adverse effects.
RECENT FINDINGS
We identified 11 eligible systematic reviews providing data from 32 studies, including 10 moderate to high quality RCTs. Five reviews concluded that there was sufficient evidence that cannabinoids may be effective for symptoms of pain and/or spasticity in MS. Few reviews reported conclusions for other symptoms. Recent high quality reviews find cannabinoids may have modest effects in MS for pain or spasticity. Future research should include studies with non-cannabinoid comparators; this is an important gap in the evidence.
目的综述
药用大麻素，如纳比西莫尔、那布隆和大麻隆，以及植物源大麻素，已被研究用于治疗多发性硬化症（MS）的多种症状。本综述旨在综合高质量系统评价的研究结果，这些评价检查了大麻素在多发性硬化症中的安全性和有效性。我们检查了残疾和残疾进展、疼痛、痉挛、膀胱功能、震颤/共济失调、生活质量和不良反应的结果。
最近的发现
我们确定了 11 项符合条件的系统评价，这些评价提供了来自 32 项研究的数据，其中包括 10 项中等到高质量的 RCT。五项综述的结论是，有充分的证据表明大麻素可能对多发性硬化症的疼痛和/或痉挛症状有效。少数综述报告了其他症状的结论。最近的高质量综述发现，大麻素可能对多发性硬化症的疼痛或痉挛有一定的疗效。未来的研究应包括使用非大麻素对照剂的研究；这是证据中的一个重要空白。
Zotero 插件